National GLP-1 Outcomes Registry-in-a-Box
A national database to track the long-term safety and effectiveness of weight-loss drugs.
A ready-to-deploy registry that tracks long-term weight, cardiometabolic, safety, and equity outcomes for every patient started on GLP-1 therapy under new national guidelines — generating the long-term evidence WHO says is missing and that kept its recommendations conditional.
Concept
One product: a configured national registry service (data model, consent workflow, annual follow-up instruments, equity dashboards, and public reporting templates) that a ministry of health or national health service switches on as it scales GLP-1 access. It captures per-patient trajectories — weight change, continuation and discontinuation, adverse events, cardiometabolic comorbidity outcomes, and access equity metrics (who actually receives therapy, by deprivation and geography) — with fixed annual follow-up so the dataset matures into the long-term evidence base WHO currently lacks. Annual public reports feed directly into eligibility-expansion decisions, giving countries a built-in feedback loop between rollout and evidence. The wedge is singular: convert every GLP-1 prescription issued under the new guideline into structured, analyzable long-term outcome data.
Why now
WHO graded both GLP-1 recommendations conditional explicitly because of limited long-term data [0], and its next guideline phase — incremental expansion of eligibility — will require exactly the real-world outcome and equity data such a registry produces. The scarcity of long-term trajectory evidence is visible in what exists today: the pooled post-cessation meta-analysis had to be assembled from scattered trials and still found adults regaining roughly 0.8 kg per month after stopping incretins [1] — a single, hard-won figure that a standing registry would produce continuously and at population scale. As countries begin large GLP-1 obesity rollouts under a guideline covering a disease affecting over 1 billion people [0], first movers will also become the only sources of long-term, population-level evidence.
Written by GLM · 10 Oct 2026
AI assessment
A high-utility infrastructure play that solves a specific regulatory bottleneck for national health systems, though it faces significant B2G sales cycles and data sovereignty hurdles.
- Evidence strength 5/5
- The idea directly addresses the 'conditional' grading of WHO guidelines due to missing long-term data and utilizes the specific regain rates from the meta-analysis to justify the need for longitudinal tracking.
- Market pull 4/5
- National health ministries and regulators have a high urgency to justify the massive spend on GLP-1s with real-world evidence, though the buyer is a slow-moving government entity.
- Novelty & moat 3/5
- While it complements existing catalog ideas (triage and exit plans), it shifts the value proposition from clinical delivery to systemic data infrastructure.
- Feasibility 4/5
- The technical build is a standard registry/dashboard system; the primary challenge is legal/regulatory (GDPR/HIPAA) rather than technical.
- Wedge clarity 5/5
- The wedge is extremely sharp: a 'registry-in-a-box' specifically for GLP-1s to enable the next phase of WHO eligibility expansion.
- Simplicity / focus 5/5
- It avoids 'platform creep' by focusing on a single, well-defined product: a configured data collection and reporting service.
Scored by Gemma 4 · 10 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- World Health Organizationorganization
Needs long-term data to upgrade its conditional GLP-1 recommendations; a standardized registry deployed across Member States supplies the evidence base for the next guideline iteration.
- Novo Nordiskcompany
Population-scale, long-term real-world safety and effectiveness data supports payer value dossiers, label defense, and access negotiations as semaglutide rolls out globally.
- Eli Lilly and Companycompany
Tirzepatide's long-term obesity outcomes are equally data-hungry; registry partnerships generate the durable evidence payers increasingly demand.
- World Obesity Federationorganization
An advocacy and research organization that would use registry-derived equity and outcome data to shape national obesity policy.
Research it builds on
- Weight regain after cessation of medication for weight management: systematic review and meta-analysisSam West, Jadine Scragg, Paul Aveyard et al. · 2026 · 161 citationsAll ideas from this paper →
- World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in AdultsFrancesca L. Celletti, Jeremy Farrar, Luz María de Regil · 2025 · 143 citationsAll ideas from this paper →